摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-3,5-dimethylphenyl)-5-(3-(6-phenyl-1,4-dioxaspiro [4.5 ]decan-6-yl)propyl)-1,2,4-oxadiazole | 1356465-32-1

中文名称
——
中文别名
——
英文名称
3-(4-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-3,5-dimethylphenyl)-5-(3-(6-phenyl-1,4-dioxaspiro [4.5 ]decan-6-yl)propyl)-1,2,4-oxadiazole
英文别名
3-(4-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-3,5-dimethylphenyl)-5-(3-(6-phenyl-1,4-dioxaspiro[4.5]decan-6-yl)propyl)-1,2,4-oxadiazole;3-[4-[[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-3,5-dimethylphenyl]-5-[3-(6-phenyl-1,4-dioxaspiro[4.5]decan-6-yl)propyl]-1,2,4-oxadiazole
3-(4-(((R)-2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)-3,5-dimethylphenyl)-5-(3-(6-phenyl-1,4-dioxaspiro [4.5 ]decan-6-yl)propyl)-1,2,4-oxadiazole化学式
CAS
1356465-32-1
化学式
C33H42N2O6
mdl
——
分子量
562.706
InChiKey
MUUUXALVZSRQJP-XIDOUCRZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    41
  • 可旋转键数:
    9
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.58
  • 拓扑面积:
    85.1
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS
    申请人:Das Jagabandhu
    公开号:US20130158001A1
    公开(公告)日:2013-06-20
    Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C 1 -C 4 alkyl, or (ii) R 1 and R 2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C 1-6 alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.
    本发明涉及式(I)的化合物:(I)或其立体异构体、盐或前药,其中:(i) R1和R2独立地是C1-C4烷基,或者(ii) R1和R2与它们连接的碳原子一起形成一个环状基团;Q为H、C1-6烷基、苯基或5-到6-成员杂环芳基取代零至3个取代基,G在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法,以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病中是有用的,例如自身免疫性疾病和慢性炎症性疾病。
  • Substituted 3-phenyl-1,2,4-Oxadiazole compounds
    申请人:Das Jagabandhu
    公开号:US08822510B2
    公开(公告)日:2014-09-02
    Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C1-6alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.
    本发明涉及式(I)的化合物:(I)或其立体异构体,盐或前药,其中:(i)R1和R2分别是C1-C4烷基,或(ii)R1和R2与它们所连接的碳原子形成一个环状基团;Q为H,C1-6烷基,苯基或0-3个取代基取代的5-至6-成员杂环芳基,G在此定义。本发明还涉及使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法,以及包括这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展,如自身免疫疾病和慢性炎症性疾病。
  • Substituted 3-phenyl-1,2,4-oxadiazole compounds
    申请人:Bristol-Myers Squibb Company
    公开号:EP2595969B1
    公开(公告)日:2015-04-22
  • US8822510B2
    申请人:——
    公开号:US8822510B2
    公开(公告)日:2014-09-02
  • [EN] SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS 3-PHÉNYL-1,2,4-OXADIAZOLE SUBSTITUÉS
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2012012477A1
    公开(公告)日:2012-01-26
    Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C1-6alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.
    本文揭示了Formula (I)的化合物:(I)或其立体异构体、盐或前药,其中:(i) R1和R2独立地为C1-C4烷基,或者(ii) R1和R2与它们连接的碳原子一起形成一个环状基团;Q为H,C1-6烷基,苯基或带有零至3个取代基的5-至6-成员杂环芳基;G在此处有定义。还揭示了使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法,以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展方面具有用途,例如自身免疫疾病和慢性炎症性疾病。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺